According to Bide Pharmaceutical's announcement, from November 13 to December 19, 2025, shareholders Zhoushan Landan Enterprise Management Partnership and their co-actors Wu Bo and Zhoushan Xinxi Enterprise Management Partnership reduced their holdings of the company's shares by a total of 1.022,400 shares, accounting for 1.12% of the total share capital. After this change in equity, the total shareholding ratio of the three was reduced from 11.12% to 10%, which is an integer multiple of 5%. The current holdings reduction fulfils the previous plan, does not touch on the proposed acquisition, and will not have a significant impact on corporate governance and operations. The holdings reduction plan has not yet been implemented.

According to Bide Pharmaceutical's announcement, from November 13 to December 19, 2025, shareholders Zhoushan Landan Enterprise Management Partnership and their co-actors Wu Bo and Zhoushan Xinxi Enterprise Management Partnership reduced their holdings of the company's shares by a total of 1.022,400 shares, accounting for 1.12% of the total share capital. After this change in equity, the total shareholding ratio of the three was reduced from 11.12% to 10%, which is an integer multiple of 5%. The current holdings reduction fulfils the previous plan, does not touch on the proposed acquisition, and will not have a significant impact on corporate governance and operations. The holdings reduction plan has not yet been implemented.